Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study ivps42019-09-27T14:24:05-05:00September 30th, 2019|Press Release| Read More
Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference ivps42019-09-11T12:16:31-05:00September 13th, 2019|Press Release| Read More
Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial ivps42019-09-06T15:14:34-05:00September 5th, 2019|Press Release| Read More
Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences ivps42019-09-04T11:56:29-05:00September 4th, 2019|Press Release| Read More
Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update ivps42019-08-08T15:45:49-05:00August 8th, 2019|Press Release| Read More
Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019 ivps42019-07-29T12:55:39-05:00July 30th, 2019|Press Release| Read More
Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation ivps42019-07-22T11:08:59-05:00July 23rd, 2019|Press Release| Read More
Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference ivps42019-06-20T12:11:56-05:00June 21st, 2019|Press Release| Read More
Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial ivps42019-06-10T19:47:43-05:00June 11th, 2019|Press Release| Read More
Achieve Receives $4.2 Million from Exercise of Warrants ivps42019-06-03T15:10:05-05:00June 3rd, 2019|Press Release| Read More